NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Sur

cafead

Administrator
Staff member
  • cafead   Jun 24, 2024 at 11:32: AM
via
  • DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide
  • Lipid-Lowering Effect of DA-1726 Shown to be Superior Compared to Tirzepatide
  • Data Presented at the ADA 84th Scientific Sessions

article source